Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clini… Read more
Shuttle Pharmaceuticals Inc (SHPH) - Total Liabilities
Latest total liabilities as of September 2025: $2.15 Million USD
Based on the latest financial reports, Shuttle Pharmaceuticals Inc (SHPH) has total liabilities worth $2.15 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shuttle Pharmaceuticals Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Shuttle Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shuttle Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Shuttle Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tokyo Plast International Limited
NSE:TOKYOPLAST
|
India | ₹648.59 Million |
|
Tower One Wireless Corp
STU:1P3N
|
Germany | €50.43 Million |
|
Inca Minerals Ltd
AU:ICG
|
Australia | AU$283.19K |
|
Sirona Biochem Corp
PINK:SRBCF
|
USA | $4.27 Million |
|
Kula Gold Ltd
AU:KGD
|
Australia | AU$620.24K |
|
Damodar Industries Limited
NSE:DAMODARIND
|
India | ₹2.04 Billion |
|
Diagnamed Holdings Corp.
PINK:DGNMF
|
USA | $666.47K |
|
ARCUS DEVELOPMENT
MU:AJR
|
Germany | €194.18K |
Liability Composition Analysis (2017–2024)
This chart breaks down Shuttle Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shuttle Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shuttle Pharmaceuticals Inc (2017–2024)
The table below shows the annual total liabilities of Shuttle Pharmaceuticals Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.80 Million | -5.21% |
| 2023-12-31 | $1.90 Million | +94.32% |
| 2022-12-31 | $975.68K | -57.20% |
| 2021-12-31 | $2.28 Million | +2.03% |
| 2020-12-31 | $2.23 Million | +276.27% |
| 2018-12-31 | $593.82K | +46.39% |
| 2017-12-31 | $405.65K | -- |